<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9441">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697692</url>
  </required_header>
  <id_info>
    <org_study_id>2128/2021</org_study_id>
    <nct_id>NCT05697692</nct_id>
  </id_info>
  <brief_title>Heparin-free Extracorporeal Membrane Oxygenation Support During Clinical Lung Transplantation</brief_title>
  <acronym>zero-hep</acronym>
  <official_title>An Investigation of Clinical Outcomes and Inflammatory Response to Heparin Free Extracorporeal Membrane Oxygenation Support During Clinical Lung Transplantation - a Prospective Double-blind Randomised Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this investigation is to compare two different anti-coagulation strategies in&#xD;
      clinical lung transplantation where lung implantations are all routinely done on&#xD;
      veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) support at the investigators'&#xD;
      institution. No heparinization (Zero-Hep) will be compared to standard low-dose&#xD;
      heparinization (Standard). Traditionally, the Vienna group has used a standard low-dose&#xD;
      heparin protocol with unfractionated heparin (UFH) administered as a bolus upon ECMO&#xD;
      cannulation. With heparin-coated tubing and intraoperative ECMO flow never falling below 1&#xD;
      L/min, the likelihood of thromboembolic events is believed to be negligible. To date, the&#xD;
      investigators have not experienced any thromboembolic events during intra-operative ECMO use.&#xD;
      On the other hand, the use of UFH entails an increased risk for bleeding, so it follows that&#xD;
      avoidance of additional heparin may be beneficial. Generally, risks and benefits of&#xD;
      heparinization during these short procedures have not yet been thoroughly analyzed. This&#xD;
      study will investigate the feasibility of running heparin free VA-ECMO support during&#xD;
      clinical lung transplantation and its effect on clinical outcomes and inflammatory response&#xD;
      comparing 40 patients receiving a standard dose of heparin versus 40 patients receiving&#xD;
      placebo in a randomized, double-blind study design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial thromboembolic events</measure>
    <time_frame>From time of intraoperative ECMO initiation, assessed uo to 3 weeks post-transplant</time_frame>
    <description>Including myocardial infarction, mesenteric infarction, hepatic infarction, spleen infarction, limb ischemia, cerebral stroke including transient ischemic attack</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous thromboembolic events</measure>
    <time_frame>From time of intraoperative ECMO initiation, assessed up to 3 weeks post-transplant</time_frame>
    <description>deep vein thrombosis, pulmonary embolism, cerebral venous or cavernous sinus thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circuit-related thrombosis</measure>
    <time_frame>From time of intraoperative ECMO initiation assessed until intraoperative ECMO decannulation</time_frame>
    <description>requiring ECMO oxygenator exchange</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 0.9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 international units (IU)/kg Heparin sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin sodium</intervention_name>
    <description>Lung transplantation on central veno-arterial ECMO with standard additional heparin</description>
    <arm_group_label>Heparin sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lung transplantation on central veno-arterial ECMO without additional heparin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Double lung transplantation&#xD;
&#xD;
          -  Age of 18 or older at the time of the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Single lung transplantation&#xD;
&#xD;
          -  Re-transplantation&#xD;
&#xD;
          -  Previous major thoracic surgery (excluding pleural drainage, video-assisted&#xD;
             thoracoscopic - (VATS) biopsy)&#xD;
&#xD;
          -  ECMO bridge to transplantation&#xD;
&#xD;
          -  Coronavirus(COVID) - acute respiratory distress syndrome (ARDS) as transplant&#xD;
             indication&#xD;
&#xD;
          -  Pre-operative anti-coagulation/anti-platelet treatment&#xD;
&#xD;
          -  Paediatric transplantation&#xD;
&#xD;
          -  Multi-organ transplantation&#xD;
&#xD;
          -  Active pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad Hoetzenecker, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna - Dept. of Thoracic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Schwarz, MD PhD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>56440</phone_ext>
    <email>stefan.a.schwarz@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna - Dept. of Thoracic Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Schwarz, MD PhD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>56440</phone_ext>
      <email>stefan.a.schwarz@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 12, 2023</study_first_submitted>
  <study_first_submitted_qc>January 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 21, 2023</last_update_submitted>
  <last_update_submitted_qc>January 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stefan Schwarz</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

